Skip to main content

Table 3 Day 4 and day 8 gametocyte prevalence adjusted for baseline gametocyte density

From: Optimal timing of primaquine to reduce Plasmodium falciparum gametocyte carriage when co-administered with artemether–lumefantrine

Variable

Gametocyte prevalence n/N

OR (95% CI)

p value

Day 4 prevalence

 AL only

8/30

Ref.

 

 AL + primaquine day 1

4/35

0.28 (0.06 – 1.37)

0.116

 AL + primaquine day 3

8/31

0.79 (0.21 – 3.00)

0.726

Day 8 prevalence

 AL only

4/30

Ref.

 

 AL + primaquine day 1

0/35

 AL + primaquine day 3

2/31

0.51 (0.07 – 3.60)

0.502

  1. AL artemether–lumefantrine, OR odds ratio, CI confidence interval